Einzelnachweise

  1. ↑ Hein T et al. Projection of the number of multiple sclerosis patients in Germany. Nervenarzt 2000; 71(4):288-94.
  2. ↑ Petersen G Regionale Unterschiede in der Prävalenz und Pharmakotherapie von Multipler Sklerose. AGENS Methodenworkshop 13.3.2013 in Berlin. URL: Zugriff über die Homepage des Zentralinstituts für kassenärztliche Versorgung in Deutschland; Zugriff am 5.2.2014.
  3. ↑ Kuusisto H et al. Concordance and heritability of multiple sclerosis in Finland: study on a nationwide series of twins. Eur J Neurol 2008;15(10):1106-10.
  4. ↑ James E et al. The effect of vitamin D-related interventions on multiple sclerosis relapses: a meta-analysis. Mult Scler Jour 2013; 19: 1571-1579.
  5. ↑ Richards RG et al. A review of the natural history and epidemiology of multiple sclerosis: implications for resource allocation and health economic models. Health Technol Assess 2002; 6(10):1-73.
  6. ↑ Swingler RJ et al. The morbidity of multiple sclerosis. Q J Med 1992; 83(300):325-37.
  7. ↑ 7,0 7,1 7,2 Richards R, Sampson F, Beard S, et al: A review of the natural history and epidemiology of multiple sclerosis: implications for resource allocation and health economic models. Health Technology Assessment 2002; 6: 1-73.
  8. ↑ Keegan BM, Noseworthy JH: Multiple Sclerosis. Annual Reviews of Medicine 2002; 53:285–302.
  9. ↑ 9,0 9,1 Liu C, Blumhardt L: Assessing relapses in treatment trials of relapsing and remitting multiple sclerosis: can we do better? Multiple Sclerosis 1999; 5: 22-28.
  10. ↑ Filippini G, Brusaferri F, Sibley W, et al: Corticosteroids or ACTH for acute exacerbations in multiple sclerosis (Cochrane review). The Cochrane Library, Issue2, 2002. Oxford: Update Software.
  11. ↑ Mohr D, Hart S, Cox D, et al: Association between stressful life events and exacerbation in multiple sclerosis: a meta-analysis. British Medical Journal 2004; 328: 731-733.
  12. ↑ Buljevac D, Flach H, Hop W, et al: Prospective study on the relationship between infections and multiple sclerosis exacerbations. Brain 2002; 125: 952-960.
  13. ↑ Confavreux C, Vukusic S, Moreau T, et al: Relapses and Progression of visability in Multiple Sclerosis. New England Journal of Medicine 2000; 343:1430–38.
  14. ↑ Kurtzke J: Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444-1452.
  15. ↑ Runmarker B et al. Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up. Brain 1993; 116(Part 1):117-34.
  16. ↑ van Waesberghe JH et al . Patterns of lesion development in multiple sclerosis: longitudinal observations with T1-weighted spin-echo and magnetization transfer MR. AJNR Am J Neuroradiol 1998; 19(4):675-83.
  17. ↑ Alonso A et al. Temporal trends in the incidence of multiple sclerosis: a systematic review. Neurology 2008;71(2):129-35.
  18. ↑ Atlas of MS Database- http://www.msif.org/about-us/advocacy/atlas/